Literature DB >> 24423305

The measurement of anti-Müllerian hormone: a critical appraisal.

Oybek Rustamov1, Alexander Smith, Stephen A Roberts, Allen P Yates, Cheryl Fitzgerald, Monica Krishnan, Luciano G Nardo, Philip W Pemberton.   

Abstract

CONTEXT: Measurement of anti-Müllerian hormone (AMH) is perceived as reliable, but the literature reveals discrepancies in reported within-subject variability and between-method conversion factors. Recent studies suggest that AMH may be prone to preanalytical instability. We therefore examined the published evidence on the performance of current and historic AMH assays in terms of the assessment of sample stability, within-patient variability, and comparability of the assay methods. EVIDENCE ACQUISITION: We reviewed studies (manuscripts or abstracts) measuring AMH, published in peer-reviewed journals between January 1, 1990, and August 1, 2013, using appropriate PubMed/Medline searches. EVIDENCE SYNTHESIS: AMH levels in specimens left at room temperature for varying periods increased by 20% in one study and by almost 60% in another, depending on duration and the AMH assay used. Even at -20°C, increased AMH concentrations were observed. An increase over expected values of 20-30% or 57%, respectively, was observed after 2-fold dilution in two linearity-of-dilution studies, but not in others. Several studies investigating within-cycle variability of AMH reported conflicting results, although most studies suggest that variability of AMH within the menstrual cycle appears to be small. However, between-sample variability without regard to menstrual cycle as well as within-sample variation appears to be higher using the GenII AMH assay than with previous assays, a fact now conceded by the kit manufacturer. Studies comparing first-generation AMH assays with each other and with the GenII assay reported widely varying differences.
CONCLUSIONS: AMH may exhibit assay-specific preanalytical instability. Robust protocols for the development and validation of commercial AMH assays are required.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24423305     DOI: 10.1210/jc.2013-3476

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study.

Authors:  Catherine Kim; Carrie Karvonen-Gutierrez; Shengchun Kong; Valerie Arends; Michael Steffes; Daniel S McConnell; John F Randolph; Siobán D Harlow
Journal:  Fertil Steril       Date:  2016-07-28       Impact factor: 7.329

Review 2.  Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Authors:  Akira Iwase; Tomoko Nakamura; Satoko Osuka; Sachiko Takikawa; Maki Goto; Fumitaka Kikkawa
Journal:  Reprod Med Biol       Date:  2015-11-23

3.  Biological variability in serum anti-Müllerian hormone throughout the menstrual cycle in ovulatory and sporadic anovulatory cycles in eumenorrheic women.

Authors:  K A Kissell; M R Danaher; E F Schisterman; J Wactawski-Wende; K A Ahrens; K Schliep; N J Perkins; L Sjaarda; J Weck; S L Mumford
Journal:  Hum Reprod       Date:  2014-06-12       Impact factor: 6.918

4.  Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome.

Authors:  Sunni L Mumford; Richard S Legro; Michael P Diamond; Christos Coutifaris; Anne Z Steiner; William D Schlaff; Ruben Alvero; Gregory M Christman; Peter R Casson; Hao Huang; Nanette Santoro; Esther Eisenberg; Heping Zhang; Marcelle I Cedars
Journal:  J Clin Endocrinol Metab       Date:  2016-05-26       Impact factor: 5.958

5.  Effect of salpingectomy, ovarian cystectomy and unilateral salpingo-oopherectomy on ovarian reserve.

Authors:  Oybek Rustamov; Monica Krishnan; Stephen A Roberts; Cheryl T Fitzgerald
Journal:  Gynecol Surg       Date:  2016-03-28

6.  Menstrual cycle characteristics of young females with occult primary ovarian insufficiency at initial diagnosis and one-year follow-up with serum amh level and antral follicle count.

Authors:  Yilmaz Guzel; Yilda Arzu Aba; Kayhan Yakin; Ozgur Oktem
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

7.  Prediction of metaphase II oocytes according to different serum Anti-Müllerian hormone (AMH) levels in antagonist ICSI cycles.

Authors:  Joyce B da Silva; Tatiana R Panaino; Maria A Tamm; Paloma Lira; Patricia C F Arêas; Ana C A Mancebo; Marcelo M de Souza; Roberto A Antunes; Maria do Carmo B de Souza
Journal:  JBRA Assist Reprod       Date:  2016-12-01

8.  Anti-müllerian Hormone During Natural Cycle Presents Significant Intra and Intercycle Variations When Measured With Fully Automated Assay.

Authors:  Laura Melado; Barbara Lawrenz; Junard Sibal; Emmanuel Abu; Carol Coughlan; Alfredo T Navarro; Human Mousavi Fatemi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-27       Impact factor: 5.555

Review 9.  Maximizing the clinical utility of antimüllerian hormone testing in women's health.

Authors:  Benjamin Leader; Valerie L Baker
Journal:  Curr Opin Obstet Gynecol       Date:  2014-08       Impact factor: 1.927

10.  AMH type II receptor and AMH gene polymorphisms are not associated with ovarian reserve, response, or outcomes in ovarian stimulation.

Authors:  Christian Cerra; William G Newman; Dalia Tohlob; Helen Byers; Gregory Horne; Stephen A Roberts; Lamiya Mohiyiddeen
Journal:  J Assist Reprod Genet       Date:  2016-05-03       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.